Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

The European Commission has just approved the prepandemic vaccine Prepandrix from GlaxoSmithKline ... application for its own prepandemic flu vaccine, Aflunov. The European Medicines Agency's ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

GSK. The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing. Influenza causes 140,000 to ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

influenza, malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily.

BURLINGAME, CA, UNITED STATES, December 30, 2024 /EINPresswire / -- Influenza Vaccine market Analysis - 2024-2031: Coherent Market Insights has released a new report titled "Influenza Vaccine ...